Abstract Search

ea0092op-09-02 | Oral Session 9: Thyroid Eye Disease | ETA2023

Preclinical pharmacokinetics and clinical exposure prediction for VRDN-003, a next-generation half-life extended antibody to the IGF-1 receptor for thyroid eye disease

Foster Kelly , Dickinson Brent , Bedian Vahe

Objective: Evidence shows that IGF-1 receptor (IGF-1R) antagonism reduces the inflammation and proptosis that occur in thyroid eye disease (TED). VRDN-001 is a full antagonist to IGF-1R, and VRDN-003 is a next-generation, half-life extended version of VRDN-001 designed to enable subcutaneous (SC) administration. We compared the in vivo pharmacokinetic (PK) parameters of VRDN-001 and VRDN-003 and used a PK model to simulate potential VRDN-003 SC dosing regimens.<p ...

1 shares

ea0092op-09-01 | Oral Session 9: Thyroid Eye Disease | ETA2023

VRDN-001, a full antagonist antibody to IGF-1 receptor: in vitro pharmacology and phase 1/2 results in patients with thyroid eye disease (TED)

Douglas Raymond , Ugradar Shoaib , Turbin Roger , Cockerham Kimberly , Tang Rosa , Nijhawan Navdeep , Kossler Andrea , Boisvert Chantal , Lee Wendy , Yen Michael , Kaufman David , Yoon Michael , Bedian Vahe , Katz Barrett

Objectives: Antagonism of the IGF-1 receptor (IGF-1R) has been shown to reduce TED-related inflammation and proptosis. VRDN-001, a high-affinity antagonist antibody to IGF-1R, has distinct pharmacological properties that may enable differentiated dosing and better efficacy than observed with other antibodies. We assessed VRDN-001 in vitro pharmacology compared with teprotumumab and clinical proof of concept in a phase 1/2 randomized controlled trial (NCT05176639)....

0 shares

Endocrine Abstracts

Preclinical pharmacokinetics and clinical exposure prediction for VRDN-003, a next-generation half-life extended antibody to the IGF-1 receptor for thyroid eye disease

VRDN-001, a full antagonist antibody to IGF-1 receptor: in vitro pharmacology and phase 1/2 results in patients with thyroid eye disease (TED)

BiosciAbstracts